Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrigs disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.
Amyotrophic Lateral Sclerosis Market contains market size and forecasts of Amyotrophic Lateral Sclerosis (ALS) in global, including the following market information:
- Global Amyotrophic Lateral Sclerosis (ALS) Market Revenue, 2017-2022, 2023-2028, ($ millions)
- Global Amyotrophic Lateral Sclerosis (ALS) Market Sales, 2017-2022, 2023-2028, (K MT)
Global top five Amyotrophic Lateral Sclerosis (ALS) companies in 2021 (%)
The global Amyotrophic Lateral Sclerosis (ALS) market was valued at 423.7 million in 2021 and is projected to reach US$ 1203 million by 2028, at a CAGR of 16.1% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Riluzole Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Amyotrophic Lateral Sclerosis (ALS) include Mitsubishi Tanabe Pharma, Sanofi, Mylan Pharma, Apotex, Glemark Generics, Covis Pharma, Sun Pharma and Lunan Pharma, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Amyotrophic Lateral Sclerosis (ALS) manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Amyotrophic Lateral Sclerosis (ALS) Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K MT)
Global Amyotrophic Lateral Sclerosis (ALS) Market Segment Percentages, by Type, 2021 (%)
- Riluzole
- Edaravone (Radicava)
- Other
Global Amyotrophic Lateral Sclerosis (ALS) Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K MT)
Global Amyotrophic Lateral Sclerosis (ALS) Market Segment Percentages, by Application, 2021 (%)
- Hospital
- Drugs Store
- Other
Global Amyotrophic Lateral Sclerosis (ALS) Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K MT)
Global Amyotrophic Lateral Sclerosis (ALS) Market Segment Percentages, By Region and Country, 2021 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Amyotrophic Lateral Sclerosis (ALS) revenues in global market, 2017-2022 (Estimated), ($ millions)
- Key companies Amyotrophic Lateral Sclerosis (ALS) revenues share in global market, 2021 (%)
- Key companies Amyotrophic Lateral Sclerosis (ALS) sales in global market, 2017-2022 (Estimated), (K MT)
- Key companies Amyotrophic Lateral Sclerosis (ALS) sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Mitsubishi Tanabe Pharma
- Sanofi
- Mylan Pharma
- Apotex
- Glemark Generics
- Covis Pharma
- Sun Pharma
- Lunan Pharma
Industry Market Size
